

Chemicals/Finland, August 21, 2023 Company update

Looking to deliver more volumes

Exel's results are yet to see demand pick up, and although valuation isn't demanding uncertainty still limits upside.

Still very soft results, however H2 should show gains


Exel's Q2 was expected to be still somewhat soft, but the EUR 25.4m revenue came in well below our EUR 34.3m estimate as e.g. Wind power and Transportation, which had high Q2'22 deliveries, saw low demand especially in North America. Many key industries continued to reduce inventories, yet Exel saw demand developing largely according to its expectations and sees its delivery volumes begin to recover towards the end of the year. Q2 revenue declined by another 12% q/q, in the light of which the EUR 0.1m adj. EBIT already showed some results in terms of lower costs. Exel has some further scope to cut costs, and achieved results in terms of margin management, yet lacking volumes left adj. EBIT far from our EUR 1.2m estimate.

Many applications have already shown promise

Raw materials prices should remain stable, and pricing hasn't been an issue for Exel, while cost cuts help results only so much. We estimate Q3 revenue to decline 11% y/y (meaning 18% q/q growth) while the EUR 35m revenue we estimate for Q4 should be enough to produce a healthy level of EBIT (we estimate EUR 2.5m Q4 EBIT). The demand and inventory cycles now produce large variations in results, and recent areas of particular softness (e.g. North American Wind power and Transportation) are also likely to make up much of the volume recovery going towards next year. Exel updates its strategy this fall; it's clear Wind power remains a key driver (e.g. the Indian JV), but there should be other products to capitalize on (incl. conductor core rods) and ways to specify growth path in e.g. Transportation and Defense.

H2 figures to reflect the pace of demand improvement

Q4 might show a strong EBIT, but we see FY '23 adj. EBIT halving to EUR 3.9m, a very modest level which means FY '23 earnings multiples are elevated (20x EV/EBIT on our estimates). Exel's valuation can't be really described as expensive since profitability is to improve from here on, and the 7.5x EV/EBIT on our FY '24 EBIT estimate of EUR 8.5m isn't that challenging especially when such a level of EBIT would still be shy relative to long-term potential, yet the fog around demand pick-up keeps uncertainty high. Our new TP is EUR 3.5 (4.3); retain HOLD rating.



Share price, EUR (Last trading day's closing price)	3.38
Target price, EUR	3.5
Latest change in recommendation	03-May-23
Latest report on company	03-May-23
Research paid by issuer:	YES
No. of shares outstanding, '000's	11,897
No. of shares fully diluted, '000's	11,897
Market cap, EURm	40
Free float, %	100.0
Exchange rate EUR/USD	1.09
Reuters code	EXL1V.HE
Bloomberg code	EXL1V FH
Average daily volume, EURm	0.1
Next interim report	03-Nov-23
Web site	www.exelcomposites.com
Analyst	Joonas Ilvonen
E-mail	joonas.ilvonen@evli.com
Telephone	+358 44 430 9071

■ BUY □ HOLD ■ SELL

KEY FIGL	IRES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2021	134.4	3.7	2.8%	-6.2	0.14	57.0	1.0	34.9	-6.5	0.20
2022	137.0	3.0	2.2%	9.4	0.18	30.1	0.7	31.4	14.6	0.20
2023E	118.8	3.3	2.8%	5.1	-0.06	-59.8	0.6	20.6	12.8	0.15
2024E	128.3	8.5	6.6%	4.7	0.38	8.9	0.5	7.6	11.7	0.20
2025E	134.7	10.8	8.0%	7.0	0.56	6.0	0.4	5.5	17.3	0.25
Market ca	p, EURm		40 G	earing 2023E,	0/0		15, %	45.9		
Net debt 2	.023E, EURm		27 P	rice/book 2023	3E		1.5 CAGR	sales 2022-	25, %	-0.6
Enterprise	value, EURm		67 D	ividend yield 2	2023E, %			-2.3		
Total asset	s 2023E, EURn	n	101 Ta	ax rate 2023E,	0/0			2.8		
Goodwill 2	2023E, EURm		13 E	quity ratio 202	23E, %			0.0		



Chemicals/Finland, August 21, 2023 Company update

Estimates and valuation

Exel Composites	2019	2020	2021	Q1'22	Q2'22	Q3'22	Q4'22	2022	Q1'23	Q2'23	Q3'23e	Q4'23e	2023e
Buildings and infrastructure	23.5	23.5	32.9	7.7	8.9	7.8	8.1	32.5	7.8	6.5	6.8	9.1	30.2
Equipment and other industries	18.6	19.5	23.4	7.4	5.9	5.6	4.3	23.1	5.6	5.0	4.9	4.9	20.4
Wind power	23.6	28.1	32.1	6.8	6.5	8.0	5.5	26.8	1.5	2.3	5.2	5.9	14.9
Machinery and electrical	14.4	15.5	17.6	4.3	5.3	5.0	5.2	19.7	4.6	4.1	4.6	5.5	18.8
Transportation	13.1	10.2	10.2	3.1	7.2	3.7	3.3	17.4	4.2	3.7	4.5	4.5	16.9
Defense	2.3	5.3	8.7	2.1	1.6	2.0	1.9	7.5	2.9	2.6	2.1	2.1	9.6
Telecommunications	8.2	6.5	9.5	2.8	2.8	1.7	2.6	10.0	2.2	1.3	1.8	2.7	8.0
Revenue	103.8	108.6	134.4	34.2	38.1	33.8	31.0	137.0	28.8	25.4	29.9	34.7	118.8
y/y change, %	7 %	5 %	24 %	10 %	14 %	1 %	-15 %	2 %	-16 %	-33 %	-11 %	12 %	-13 %
Adjusted EBIT	7.2	9.7	6.0	2.2	3.1	1.8	0.9	8.0	0.0	0.1	1.3	2.5	3.9
EBIT	5.1	9.4	3.7	0.0	3.0	1.7	-1.7	3.0	-0.3	-0.2			3.3
-margin, %	6.9 %	8.9 %	4.5 %	6.4 %	8.2 %	5.4 %	3.0 %	5.9 %	0.0 %	0.3 %	4.3 %	7.2 %	3.3 %
-margin (reported), %	4.9 %	8.7 %	2.8 %	0.1 %	7.9 %	5.0 %	-5.5 %	2.2 %	-1.0 %	-1.0 %			2.8 %

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	22	23	24	22	23	24	22	23	24
Hexagon Composites	534			14.1x			33.9x	-8.0 %	-7.8 %	3.5 %
Hexcel	5455	19.0x	17.8x	14.9x	31.6x	27.3x	21.4x	11.4 %	13.4 %	15.5 %
Avient	3107	8.0x	9.6x	8.6x	11.7x	16.1x	13.3x	11.9 %	9.6 %	11.0 %
SGL Carbon	878	6.0x	7.6x	5.6x	9.9x	10.9x	8.4x	9.9 %	8.6 %	10.5 %
TPI Composites	189	13.1x		8.4x			17.5x	-1.6 %	-4.3 %	2.3 %
Peer Group Average	2033	11.5x	11.7x	10.3x	17.7x	18.1x	18.9x	4.7 %	3.9 %	8.6 %
Peer Group Median	878	10.6x	9.6x	8.6x	11.7x	16.1x	17.5x	9.9 %	8.6 %	10.5 %
Exel Composites (Evli est.)	40	9.3x	6.9x	4.5x	31.4x	20.6x	7.6x	2.2 %	2.8 %	6.6 %
Exel Composites prem./disc. to peer med	lian	-12%	-28 %	-48 %	168 %	27 %	-57 %	-78 %	-68 %	-37 %

Source FactSet, Evli Research

Chemicals/Finland, August 21, 2023 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	3.38 PV of Free Cash Flow	72 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	10.84 PV of Horizon value	89 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	220.6 Unconsolidated equity	O Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	11.9 Marketable securities	17 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	9.9 Debt - dividend	-50 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	55.5 Value of stock	129 Nr of shares, Mn	11.9 Effective tax rate, %	21

DCE valuation ELIDm	2022	2022E	2024E	202EE	2026E	2027E	2028E	2020E	2020E	2021E	2022E	Номітою
DCF valuation, EURm	2022	2023E	2024E	2025E				2029E	2030E	2031E	2032E	
Net sales	137	119	128	135	139	142	144	147	150	153	156	158
Sales growth, %	2.0	-13.3	8.0	5.0	3.0	2.0	2.0	2.0	2.0	2.0	1.5	1.5
Operating income (EBIT)	3	3	8	11	12	15	16	17	17	18	18	18
Operating income margin, %	2.2	2.8	6.6	8.0	9.0	10.5	11.0	11.5	11.5	11.5	11.5	11.5
+ Depreciation+amort.	7	6	6	6	5	5	5	4	4	4	4	
EBITDA	10	10	14	16	18	20	20	21	22	22	22	
- Paid taxes	-1	-2	-3	-3	-3	-4	-4	-4	-4	-4	-4	
- Change in NWC	3	3	-1	-1	-1	0	0	0	0	0	0	
NWC / Sales, %	10.3	9.6	10.0	10.2	10.4	10.5	10.6	10.6	10.7	10.8	10.9	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-3	-3	-4	-4	-4	-4	-4	-4	-4	-4	-4	
opCAPEX / Sales, %	2.4	2.8	3.3	3.2	3.1	2.8	2.8	2.8	2.8	2.8	2.8	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	9	7	7	9	10	12	12	13	13	13	13	193
= Discounted FCFF		7	6	7	8	8	8	8	7	7	6	89
	•	•	•		•	•	•	•				
= DFCF min WACC	•	7	6	7	8	8	8	8	7	7	6	101
= DFCF max WACC	•	7	6	7	8	8	8	7	7	6	6	80

Chemicals/Finland, August 21, 2023 Company update

INTERIM FIGURES

EVALUECTIMATES FUR	222224					222224		222225	0000045	2222	22245	22255
EVLI ESTIMATES, EURm	2022Q1	2022Q2	2022Q3	2022Q4	2022	2023Q1	2023Q2	2023Q3E	2023Q4E	2023E	2024E	2025E
Net sales	34.2	38.1	33.8	31.0	137.0	28.8	25.4	29.9	34.7	118.8	128.3	134.7
EBITDA	1.8	4.8	3.6	0.0	10.1	1.5	1.5	2.8	4.0	9.7	14.4	16.3
EBITDA margin (%)	5.2	12.5	10.5	0.0	7.4	5.3	5.7	9.3	11.4	8.2	11.2	12.1
EBIT	0.0	3.0	1.7	-1.7	3.0	-0.3	-0.2	1.3	2.5	3.3	8.5	10.8
EBIT margin (%)	0.1	7.9	5.0	-5.5	2.2	-1.0	-1.0	4.3	7.2	2.8	6.6	8.0
Net financial items	0.5	1.9	1.6	-3.4	0.6	-1.2	-0.4	-0.4	-0.2	-2.2	-2.0	-1.9
Pre-tax profit	0.5	4.9	3.3	-5.1	3.6	-1.5	-0.7	0.9	2.3	1.0	6.5	8.9
Tax	-0.6	-0.9	-1.2	1.2	-1.5	-0.6	-0.2	-0.3	-0.5	-1.7	-2.0	-2.2
Tax rate (%)	111.4	19.3	35.6	24.3	40.4	-43.8	-36.3	33.3	21.7	165.4	30.7	25.0
Net profit	-0.1	4.0	2.1	-3.9	2.1	-2.1	-0.9	0.6	1.8	-0.7	4.5	6.7
EPS	-0.01	0.33	0.18	-0.33	0.18	-0.18	-0.08	0.05	0.15	-0.06	0.38	0.56
EPS adjusted (diluted no. of shares)	-0.01	0.33	0.18	-0.33	0.18	-0.18	-0.08	0.05	0.15	-0.06	0.38	0.56
Dividend per share	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.15	0.20	0.25
SALES, EURm												
Exel Composites	34.2	38.1	33.8	31.0	137.0	28.8	25.4	29.9	34.7	118.8	128.3	134.7
Total	34.2	38.1	33.8	31.0	137.0	28.8	25.4	29.9	34.7	118.8	128.3	134.7
SALES GROWTH, Y/Y %												
Exel Composites	10.3	13.5	1.2	-15.1	2.0	-15.7	-33.3	-11.5	11.9	-13.3	8.0	5.0
Total	10.3	13.5	1.2	-15.1	2.0	-15.7	-33.3	-11.5	11.9	-13.3	8.0	5.0
EBIT, EURm												
Exel Composites	0.0	3.0	1.7	-1.7	3.0	-0.3	-0.2	1.3	2.5	3.3	8.5	10.8
Total	0.0	3.0	1.7	-1.7	3.0	-0.3	-0.2	1.3	2.5	3.3	8.5	10.8
EBIT margin, %												
Exel Composites	0.1	7.9	5.0	-5.5	2.2	-1.0	-1.0	4.3	7.2	2.8	6.6	8.0
Total	0.1	7.9	5.0	-5.5	2.2	-1.0	-1.0	4.3	7.2	2.8	6.6	8.0

Chemicals/Finland, August 21, 2023 Company update

INCOME STATEMENT, EURm	2018	2019	2020	2021	2022	2023E	2024E	2025E
Sales	96.6	103.8	108.6	134.4	137.0	118.8	128.3	134.7
Sales growth (%)	11.9	7.5	4.6	23.7	2.0	-13.3	8.0	5.0
EBITDA	7.7	10.7	15.3	11.9	10.1	9.7	14.4	16.3
EBITDA margin (%)	8.0	10.3	14.1	8.9	7.4	8.2	11.2	12.1
Depreciation	-5.5	-5.6	-5.8	-8.2	-7.1	-6.4	-5.9	-5.5
EBITA	2.2	5.1	9.4	3.7	3.0	3.3	8.5	10.8
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	2.2	5.1	9.4	3.7	3.0	3.3	8.5	10.8
EBIT margin (%)	2.3	4.9	8.7	2.8	2.2	2.8	6.6	8.0
Reported EBIT	2.2	5.1	9.4	3.7	3.0	3.3	8.5	10.8
EBIT margin (reported) (%)	2.3	4.9	8.7	2.8	2.2	2.8	6.6	8.0
Net financials	-0.5	-1.2	-2.3	0.4	0.6	-2.2	-2.0	-1.9
Pre-tax profit	1.7	3.9	7.1	4.2	3.6	1.0	6.5	8.9
Taxes	-1.3	-1.5	-1.7	-2.5	-1.5	-1.7	-2.0	-2.2
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	0.4	2.4	5.4	1.7	2.1	-0.7	4.5	6.7
Cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Assets								
Fixed assets	21	23	30	34	31	28	26	25
Goodwill	13	13	13	13	13	13	13	13
Right of use assets	5	5	3	3	2	2	2	2
Inventory	15	17	16	24	23	20	22	23
Receivables	20	20	21	26	23	20	23	23
Liquid funds	5	7	12	16	17	15	16	17
Total assets	79	85	97	118	113	101	104	106
Liabilities	75	65	37	110	113	101	104	100
Shareholder's equity	26	26	29	31	30	27	30	34
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	3	4	2	2	1	2	2	2
Deferred taxes	0	0	0	0	1	1	1	1
	30	32	40	50	46	40	38	34
Interest bearing debt	18	21		32			36 25	26
Non-interest bearing current liabilities			24		26	23		
Other interest-free debt Total liabilities	2 79	2 85	2 97	3 118	9 113	9 101	9 104	9 106
CASH FLOW, EURm	75	65	37	110	113	101	104	100
+ EBITDA	8	11	15	12	10	10	14	16
- Net financial items	0	-1	-2	0	10	-2	-2	-2
- Taxes					-1	-2 -2		
	-2	-2	-2 3	-3 -5	-1 3	-2 3	-2	-2
- Increase in Net Working Capital	-4	1					-1	-1
+/- Other	0	0	0	0	0	0	0	0
= Cash flow from operations	1	8	13	5	13	8	9	11
- Capex	-10	-8	-13	-11	-3	-3	-4	-4
- Acquisitions	0	0	0	0	0	0	0	0
+ Divestments	0	0	0	0	0	0	0	0
= Free cash flow	-9	1	0	-6	9	5	5	7
+/- New issues/buybacks	0	0	-1	3	-1	0	0	0
- Paid dividend	-4	-2	-2	-2	-2	-2	-2	-2
+/- Other	9	3	7	9	-5	-5	-2	-4
Change in cash	-3	2	5	4	2	-2	1	1

Chemicals/Finland, August 21, 2023 Company update

KEY FIGURES	2019	2020	2021	2022	2023E	2024E	2025E
M-cap	78	88	94	64	40	40	40
Net debt (excl. convertibles)	29	30	36	30	27	24	20
Enterprise value	107	118	131	94	67	64	60
Sales	104	109	134	137	119	128	135
EBITDA	11	15	12	10	10	14	16
EBIT	5	9	4	3	3	8	11
Pre-tax	4	7	4	4	1	7	9
Earnings	2	5	2	2	-1	5	7
Equity book value (excl. minorities)	26	29	31	30	27	30	34
Valuation multiples							
EV/sales	1.0	1.1	1.0	0.7	0.6	0.5	0.4
EV/EBITDA	10.0	7.7	10.9	9.3	6.9	4.5	3.7
EV/EBITA	21.0	12.5	34.9	31.4	20.6	7.6	5.5
EV/EBIT	21.0	12.5	34.9	31.4	20.6	7.6	5.5
EV/OCF	12.9	8.8	27.2	7.4	7.9	7.2	5.3
EV/FCFF	32.5	52.9	-26.0	10.2	9.4	9.6	6.6
P/FCFE	110.9	179.1	-15.3	6.8	7.8	8.5	5.8
P/E	32.5	16.4	57.0	30.1	-59.8	8.9	6.0
P/B	3.0	3.1	3.0	2.1	1.5	1.3	1.2
Target EV/EBITDA	0.0	0.0	0.0	0.0	7.1	4.6	3.7
Target EV/EBIT	0.0	0.0	0.0	0.0	21.0	7.8	5.7 5.7
Target EV/FCF	0.0	0.0	0.0	0.0	13.3	7.8 14.0	5.7 8.8
Target P/B	0.0	0.0	0.0		13.3 1.5	1.4	
9 ·				0.0			1.2
Target P/E	0.0	0.0	0.0	0.0	-62.0	9.2	6.3
Per share measures Number of shares	11.007	11.007	11.007	11.007	11.007	11 007	11.007
	11,897	11,897	11,897	11,897	11,897	11,897	11,897
Number of shares (diluted)	11,897	11,897	11,897	11,897	11,897	11,897	11,897
EPS	0.20	0.45	0.14	0.18	-0.06	0.38	0.56
Operating cash flow per share	0.70	1.12	0.40	1.06	0.71	0.76	0.95
Free cash flow per share	0.06	0.04	-0.52	0.79	0.43	0.40	0.58
Book value per share	2.21	2.41	2.62	2.56	2.30	2.53	2.89
Dividend per share	0.18	0.20	0.20	0.20	0.15	0.20	0.25
Dividend payout ratio, %	89.2	44.3	143.7	110.9	-265.6	52.8	44.7
Dividend yield, %	2.7	2.7	2.5	3.7	4.4	5.9	7.4
FCF yield, %							
•	0.9	0.6	-6.5	14.6	12.8	11.7	17.3
Efficiency measures							
Efficiency measures ROE	9.2	19.5	5.5	7.0	-2.3	15.7	20.7
Efficiency measures ROE ROCE							
Efficiency measures ROE	9.2	19.5	5.5	7.0	-2.3	15.7	20.7
Efficiency measures ROE ROCE Financial ratios Inventories as % of sales	9.2 8.6	19.5 14.4 14.9	5.5 5.1 17.8	7.0 4.0	-2.3 2.8	15.7	20.7
Efficiency measures ROE ROCE Financial ratios	9.2 8.6	19.5 14.4	5.5 5.1	7.0 4.0	-2.3 2.8	15.7 10.7	20.7 13.8
Efficiency measures ROE ROCE Financial ratios Inventories as % of sales	9.2 8.6	19.5 14.4 14.9	5.5 5.1 17.8	7.0 4.0	-2.3 2.8	15.7 10.7 17.1	20.7 13.8 17.1
Efficiency measures ROE ROCE Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, %	9.2 8.6 16.3 19.2	19.5 14.4 14.9 19.2	5.5 5.1 17.8 19.6	7.0 4.0 17.1 17.8	-2.3 2.8 17.1 17.9	15.7 10.7 17.1 17.8	20.7 13.8 17.1 17.8
Efficiency measures ROE ROCE Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales	9.2 8.6 16.3 19.2 20.2	19.5 14.4 14.9 19.2 22.0	5.5 5.1 17.8 19.6 23.8	7.0 4.0 17.1 17.8 19.1	-2.3 2.8 17.1 17.9 19.1	15.7 10.7 17.1 17.8 19.1	20.7 13.8 17.1 17.8 19.1
Efficiency measures ROE ROCE Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, %	9.2 8.6 16.3 19.2 20.2 14.1	19.5 14.4 14.9 19.2 22.0 11.2	5.5 5.1 17.8 19.6 23.8 12.7	7.0 4.0 17.1 17.8 19.1 10.3	-2.3 2.8 17.1 17.9 19.1 9.6	15.7 10.7 17.1 17.8 19.1 10.0	20.7 13.8 17.1 17.8 19.1 10.2
Efficiency measures ROE ROCE Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, %	9.2 8.6 16.3 19.2 20.2 14.1 7.3	19.5 14.4 14.9 19.2 22.0 11.2 11.9	5.5 5.1 17.8 19.6 23.8 12.7 8.2	7.0 4.0 17.1 17.8 19.1 10.3 2.4	-2.3 2.8 17.1 17.9 19.1 9.6 2.8	15.7 10.7 17.1 17.8 19.1 10.0 3.3	20.7 13.8 17.1 17.8 19.1 10.2 3.2
Efficiency measures ROE ROCE Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	9.2 8.6 16.3 19.2 20.2 14.1 7.3 7.3	19.5 14.4 14.9 19.2 22.0 11.2 11.9	5.5 5.1 17.8 19.6 23.8 12.7 8.2 8.2	7.0 4.0 17.1 17.8 19.1 10.3 2.4 2.4	-2.3 2.8 17.1 17.9 19.1 9.6 2.8 2.8	15.7 10.7 17.1 17.8 19.1 10.0 3.3 3.3	20.7 13.8 17.1 17.8 19.1 10.2 3.2 3.2
Efficiency measures ROE ROCE Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	9.2 8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3	19.5 14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1	5.5 5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4	7.0 4.0 17.1 17.8 19.1 10.3 2.4 2.4 0.9	-2.3 2.8 17.1 17.9 19.1 9.6 2.8 2.8 0.7	15.7 10.7 17.1 17.8 19.1 10.0 3.3 3.3 0.5	20.7 13.8 17.1 17.8 19.1 10.2 3.2 3.2 0.6
Efficiency measures ROE ROCE Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	9.2 8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3 2.7	19.5 14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1 2.0	5.5 5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4 3.0	7.0 4.0 17.1 17.8 19.1 10.3 2.4 2.4 0.9 2.9	-2.3 2.8 17.1 17.9 19.1 9.6 2.8 2.8 0.7 2.8	15.7 10.7 17.1 17.8 19.1 10.0 3.3 3.3 0.5 1.7	20.7 13.8 17.1 17.8 19.1 10.2 3.2 3.2 0.6 1.2

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, August 21, 2023 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	%
Sijoitusrahasto Taaleritehdas Mikro Markka	800,000	2.704	6.7%
OP-Finland Small Firms Fund	590,119	1.995	5.0%
Ilmarinen Mutual Pension Insurance	496,547	1.678	4.2%
Op-Suomi Mikroyhtiöt -Erikoissijoitusrahasto	420,000	1.420	3.5%
Phoebus Fund	370,000	1.251	3.1%
Säästöpankki Pienyhtiöt	288,710	0.976	2.4%
Nelimarkka Heikki Antero	213,545	0.722	1.8%
Veritas Pension Insurance Company Ltd.	207,479	0.701	1.7%
Säästöpankki Kotimaa	132,680	0.448	1.1%
Sumato Oy	131,821	0.446	1.1%
Ten largest	3,650,901	12.340	31%
Residual	8,245,942	27.871	69%
Total	11,896,843	40.211	100%

EARNINGS CALENDAR	
November 03, 2023	Q3 report
OTHER EVENTS	
OTHER EVENTS	

COMPANY MISCELLANEOUS	
CEO: Paul Sohlberg	Mäkituvantie 5 01510 Vantaa
CFO: Mikko Rummukainen	Tel: +358 20 7541 200
IR: Sanna Ahvenniemi	

Chemicals/Finland, August 21, 2023 Company update

DEFINITIONS

extraord. items and taxes– income taxes + minority interest Number of shares
lividend for the financial period per share
eash flow)
Net financial items – Taxes – Increase in working apital – Cash NRIs ± Other adjustments
ow)
n flow – operative CAPEX – acquisitions + divestments
Free cash flow Market cap
(/sales
l expenditure – divestments – acquisitions Sales
ital
Current assets – current liabilities
d/Share
tal assets – non-interest bearing debt Number of shares
Net debt Equity
Interest bearing debt ers' equity + minority interest + taxed provisions
rs' equity + minority interest + taxed provisions Total assets – interest-free loans
e annual growth rate = Average growth per year

Chemicals/Finland, August 21, 2023 Company update

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Plc. Production of the investment recommendation has been concluded on [21.8.2023, 9:10]. This report has been published on [21.8.2023, 9:30].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, August 21, 2023 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, August 21, 2023 Company update

Contact information SALES, TRADING AND RESEARCH

Equity, ETF and Derivatives Sales		Trading	
Joachim Dannberg Ari Laine Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9115 +358 9 4766 9130	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Ronkanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120

Structured Investments Equity Research

Heikki Savijoki	+358 9 4766 9726	Arttu Heikura	+358 40 082 8098
Aki Lakkisto	+358 9 4766 9123	Joonas Ilvonen	+358 44 430 9071
		Jerker Salokivi	+358 9 4766 9149

Evli Investment Solutions

Johannes Asuja +358 9 4766 9205



EVLI PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000